Ariane Herrick

List of Publications by Year
in descending order

309 papers	17,940 citations	18436 62 h-index	16605 123 g-index
313 all docs	313 docs citations	313 times ranked	12343 citing authors

#	Article	IF	Citations
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.5	1,705
3	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.5	794
4	Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis and Rheumatism, 2004, 50, 3985-3993.	6.7	656
5	A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis and Rheumatism, 2006, 54, 3962-3970.	6.7	632
6	Recombinant human antiâ€“transforming growth factor Î²1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis and Rheumatism, 2007, 56, 323-333.	6.7	415
7	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nature Genetics, 2010, 42, 426-429.	9.4	351
8	Pathogenesis of Raynaud's phenomenon. Rheumatology, 2005, 44, 587-596.	0.9	339
9	Heterozygous Mutations in TREX1 Cause Familial Chilblain Lupus and Dominant Aicardi-GoutiÃ¨res Syndrome. American Journal of Human Genetics, 2007, 80, 811-815.	2.6	339
10	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. Autoimmunity Reviews, 2020, 19, 102458.	2.5	231
11	The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nature Reviews Rheumatology, 2012, 8, 469-479.	3.5	228
12	Interferon-? does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 1999, 42, 299-305.	6.7	201
13	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. PLoS Genetics, 2011, 7, e1002178.	1.5	201
14	Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	2.6	182
15	Digital ulcers in systemic sclerosis. Rheumatology, 2017, 56, 14-25.	0.9	155
16	Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care and Research, 2010, 62, 213-218.	1.5	147
17	BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology, 2016, 55, 1906-1910.	0.9	147
18	HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	3.3	139

#	Article	IF	Citations
19	Seventeen-point dermal ultrasound scoring system--a reliable measure of skin thickness in patients with systemic sclerosis. British Journal of Rheumatology, 2003, 42, 1559-1563.	2.5	135
20	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Annals of the Rheumatic Diseases, 2017, 76, 270-276.	0.5	132
21	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. Arthritis and Rheumatology, 2016, 68, 2527-2539.	2.9	122
22	An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. Rheumatology, 2016, 55, 883-890.	0.9	121
23	Vascular function in systemic sclerosis. Current Opinion in Rheumatology, 2000, 12, 527-533.	2.0	109
24	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis and Rheumatism, 2008, 59, 699-705.	6.7	109
25	Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.. Annals of the Rheumatic Diseases, 1996, 55, 122-127.	0.5	108
26	Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology, 2015, 54, 2015-2024.	0.9	108
27	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 2017, 76, 1207-1218.	0.5	107
28	Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis and Rheumatism, 2009, 61, 1103-1111.	6.7	106
29	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications, 2019, 10, 4955.	5.8	100
30	Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis. Annals of the Rheumatic Diseases, 1998, 57, 70-78.	0.5	98
31	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Human Molecular Genetics, 2012, 21, 2825-2835.	1.4	98
32	Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. , 1999, 189, 273-278.		96
33	Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology, 2002, 41, 324-328.	0.9	95
34	The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Human Pathology, 2006, 37, 190-197.	1.1	93
35	Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis and Rheumatism, 2002, 46, 3312-3316.	6.7	91
36	Epidemiology of systemic sclerosis. Best Practice and Research in Clinical Rheumatology, 2010, 24, 857-869.	1.4	90

#	Article	IF	Citations
37	Clinical Utility of Random Antiâ€“Tumor Necrosis Factor Drugâ€“Level Testing and Measurement of Antidrug Antibodies on the Longâ€Term Treatment Response in Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2011-2019.	2.9	90
38	The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon. Rheumatology, 2007, 46, 533-538.	0.9	87
39	Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 775-782.	6.7	86
40	Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis and Rheumatism, 2010, 62, 2595-2604.	6.7	85
41	The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clinical and Experimental Rheumatology, 2001, 19, 4-8.	0.4	83
42	Ocular Manifestations of Scleroderma. Survey of Ophthalmology, 2009, 54, 292-304.	1.7	82
43	Laser Doppler imaging: a developing technique for application in the rheumatic diseases. British Journal of Rheumatology, 2004, 43, 1210-1218.	2.5	80
44	Computerized nailfold video capillaroscopy--a new tool for assessment of Raynaud's phenomenon. Journal of Rheumatology, 2005, 32, 841-8.	1.0	80
45	Quantitation of microcirculatory abnormalities in patients with primary Raynaud's phenomenon and systemic sclerosis by video capillaroscopy. Rheumatology, 2000, 39, 506-512.	0.9	79
46	Acro-osteolysis in systemic sclerosis is associated with digital ischaemia and severe calcinosis. Rheumatology, 2012, 51, 2234-2238.	0.9	79
47	Fast track algorithm: How to differentiate a â€œscleroderma patternâ€•from a â€œnon-scleroderma patternâ€• Autoimmunity Reviews, 2019, 18, 102394.	2.5	79
48	Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Annals of the Rheumatic Diseases, 2002, 61, 1007-1011.	0.5	78
49	Raynaud's phenomenon. Best Practice and Research in Clinical Rheumatology, 2016, 30, 112-132.	1.4	78
50	ESVM guidelines â€“ the diagnosis and management of Raynaudâ€™s phenomenon. Vasa - European Journal of Vascular Medicine, 2017, 46, 413-423.	0.6	78
51	A rare polymorphism in the gene for Tollâ€like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. Arthritis and Rheumatism, 2012, 64, 264-271.	6.7	77
52	Systemic sclerosis. British Journal of Hospital Medicine (London, England: 2005), 2019, 80, 530-536.	0.2	75
53	Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. Journal of Rheumatology, 1994, 21, 1477-83.	1.0	75
54	CONTROLLED TRIAL OF HAEM ARGINATE IN ACUTE HEPATIC PORPHYRIA. Lancet, The, 1989, 333, 1295-1297.	6.3	74

#	Article	IF	Citations
55	A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Human Molecular Genetics, 2012, 21, 926-933.	1.4	74
56	Nailfold video capillaroscopy in psoriasis. British Journal of Dermatology, 2000, 142, 1171-1176.	1.4	72
57	Prolidase deficiency and systemic lupus erythematosus. Archives of Disease in Childhood, 1997, 76, 441-444.	1.0	70
58	Comparison of thermography and laser Doppler imaging in the assessment of Raynaudâ€™s phenomenon. Microvascular Research, 2003, 66, 73-76.	1.1	68
59	Acute intermittent porphyria. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 235-249.	1.0	66
60	Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. Seminars in Arthritis and Rheumatism, 2016, 46, 344-349.	1.6	66
61	Laser Doppler Imagingâ€"A New Technique for Quantifying Microcirculatory Flow in Patients with Primary Raynaud's Phenomenon and Systemic Sclerosis. Microvascular Research, 1999, 57, 284-291.	1.1	65
62	A multicentre study on the reliability of qualitative and quantitative nail-fold videocapillaroscopy assessment. Rheumatology, 2012, 51, 749-755.	0.9	65
63	A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography. Arthritis and Rheumatology, 2018, 70, 903-911.	2.9	65
64	Diagnosis and Management of Scleroderma Peripheral Vascular Disease. Rheumatic Disease Clinics of North America, 2008, 34, 89-114.	0.8	63
65	A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Annals of the Rheumatic Diseases, 2011, 70, 638-641.	0.5	63
66	TGFÎ²â€"a role in systemic sclerosis?. , 1998, 184, 4-6.		62
67	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. Journal of Scleroderma and Related Disorders, 2017, 2, 115-120.	1.0	62
68	A study comparing videocapillaroscopy and dermoscopy in the assessment of nailfold capillaries in patients with systemic sclerosisâ€"spectrum disorders. Rheumatology, 2015, 54, 1435-1442.	0.9	60
69	Reliability of simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases. Rheumatology, 2018, 57, 757-759.	0.9	60
70	Malnutrition in systemic sclerosis. Rheumatology, 2012, 51, 1747-1756.	0.9	59
71	Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia.. Annals of the Rheumatic Diseases, 1994, 53, 540-542.	0.5	58
72	INCREASED NAILFOLD CAPILLARY DIMENSIONS IN PRIMARY RAYNAUD'S PHENOMENON AND SYSTEMIC SCLEROSIS. Rheumatology, 1996, 35, 1127-1131.	0.9	57

#	Article	IF	Citations
73	Confirmation ofTNIP1but notRHOBandPSORS1C1as systemic sclerosis risk factors in a large independent replication study. Annals of the Rheumatic Diseases, 2013, 72, 602-607.	0.5	56
74	Comparison of enalapril and atenolol in mild to moderate hypertension. American Journal of Medicine, 1989, 86, 421-426.	0.6	55
75	Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Current Opinion in Rheumatology, 2011, 23, 555-561.	2.0	55
76	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. Arthritis Care and Research, 2018, 70, 1373-1384.	1.5	54
77	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 2018, 57, 370-381.	0.9	53
78	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology, 2018, 57, 1623-1631.	0.9	53
79	New insight on the Xq28 association with systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 2032-2038.	0.5	52
80	Observational Study of Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis. Journal of Rheumatology, 2010, 37, 116-124.	1.0	51
81	Thumb Involvement in Raynaudâ€™s Phenomenon as an Indicator of Underlying Connective Tissue Disease. Journal of Rheumatology, 2010, 37, 783-786.	1.0	51
82	Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation.. Annals of the Rheumatic Diseases, 1994, 53, 323-326.	0.5	50
83	Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis. Arthritis and Rheumatism, 2009, 60, 878-882.	6.7	50
84	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Annals of the Rheumatic Diseases, 2018, 77, 563-570.	0.5	50
85	Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis. Rheumatology, 2006, 45, 1349-1355.	0.9	49
86	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	1.5	49
87	Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 2370-2379.	2.9	49
88	Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. Clinical Rheumatology, 2014, 33, 207-214.	1.0	48
89	A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clinical and Experimental Rheumatology, 2000, 18, 349-56.	0.4	48
90	A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact. Scandinavian Journal of Rheumatology, 2013, 42, 483-486.	0.6	47

#	Article	IF	Citations
91	Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Crossâ€Disease Metaâ€Analysis of Genomeâ€Wide Association Studies. Arthritis and Rheumatology, 2016, 68, 2338-2344.	2.9	46
92	Digital iontophoresis of vasoactive substances as measured by laser Doppler imagingâ€”a non-invasive technique by which to measure microvascular dysfunction in Raynaud's phenomenon. Rheumatology, 2004, 43, 986-991.	0.9	45
93	Outcome measurements in scleroderma: results from a delphi exercise. Journal of Rheumatology, 2007, 34, 501-9.	1.0	45
94	Validation of a Novel Radiographic Scoring System for Calcinosis Affecting the Hands of Patients With Systemic Sclerosis. Arthritis Care and Research, 2015, 67, 425-430.	1.5	44
95	Raynaud's phenomenon. Best Practice and Research in Clinical Rheumatology, 2020, 34, 101474.	1.4	43
96	Prediction and impact of attacks of Raynaudâ€™s phenomenon, as judged by patient perception. Rheumatology, 2015, 54, 1443-1447.	0.9	42
97	Genetic epidemiology: systemic sclerosis. Arthritis Research, 2002, 4, 165.	2.0	41
98	Home parenteral nutrition--an effective and safe long-term therapy for systemic sclerosis-related intestinal failure. Rheumatology, 2007, 47, 176-179.	0.9	41
99	Management of Raynaudâ€™s Phenomenon and Digital Ischemia. Current Rheumatology Reports, 2013, 15, 303.	2.1	41
100	Influence ofTYK2in systemic sclerosis susceptibility: a newlocusin the IL-12 pathway. Annals of the Rheumatic Diseases, 2016, 75, 1521-1526.	0.5	41
101	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis and Rheumatology, 2019, 71, 964-971.	2.9	41
102	Occurrence of Raynaud's phenomenon in children ages 12-15 years: Prevalence and association with other common symptoms. Arthritis and Rheumatism, 2003, 48, 3518-3521.	6.7	39
103	Reliability of dermoscopy in the assessment of patients with Raynaud's phenomenon. Rheumatology, 2010, 49, 542-547.	0.9	38
104	Nailfold Capillaroscopy in Pediatrics. Arthritis Care and Research, 2013, 65, 1393-1400.	1.5	38
105	The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis. PLoS ONE, 2013, 8, e54419.	1.1	38
106	Plasma TGF beta in systemic sclerosis: a cross-sectional study.. Annals of the Rheumatic Diseases, 1994, 53, 763-767.	0.5	37
107	Abnormal microvascular response is localized to the digits in patients with systemic sclerosis. Arthritis and Rheumatism, 2006, 54, 1952-1960.	6.7	37
108	Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy. Rheumatology, 2010, 49, 1699-1705.	0.9	37

#	Article	IF	Citations
109	A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Research and Therapy, 2014, 16, R6.	1.6	37
110	Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis. Rheumatology, 2009, 48, 876-882.	0.9	36
111	Sparing of the thumb in Raynaud's phenomenon. Rheumatology, 2007, 47, 219-221.	0.9	35
112	Nail-fold capillary abnormalities are associated with anti-centromere antibody and severity of digital ischaemia. Rheumatology, 2010, 49, 1776-1782.	0.9	35
113	Influence of Childhood Scleroderma on Physical Function and Quality of Life. Journal of Rheumatology, 2011, 38, 167-173.	1.0	35
114	Calcium channel blockers for primary Raynaud's phenomenon. The Cochrane Library, 2016, 2016, CD002069.	1.5	35
115	Foot problems in patients with systemic sclerosis. British Journal of Rheumatology, 2001, 40, 410-413.	2.5	34
116	Influence of the IL6 Gene in Susceptibility to Systemic Sclerosis. Journal of Rheumatology, 2012, 39, 2294-2302.	1.0	34
117	Treatment of Raynaudâ€™s phenomenon: New insights and developments. Current Rheumatology Reports, 2003, 5, 168-174.	2.1	33
118	Reduced perfusion in systemic sclerosis digital ulcers (both fingertip and extensor) can be increased by topical application of glyceryl trinitrate. Microvascular Research, 2017, 111, 32-36.	1.1	33
119	An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaudâ€™s phEnomenon (SUNSHINE survey). Rheumatology International, 2017, 37, 1879-1890.	1.5	33
120	The role of capillaroscopy and thermography in the assessment and management of Raynaud's phenomenon. Autoimmunity Reviews, 2018, 17, 465-472.	2.5	33
121	Patient-reported outcome instruments for assessing Raynaudâ€™s phenomenon in systemic sclerosis: A SCTC vascular working group report. Journal of Scleroderma and Related Disorders, 2018, 3, 249-252.	1.0	33
122	Antibodies against oxidized low-density lipoproteins in systemic sclerosis. British Journal of Rheumatology, 2001, 40, 401-405.	2.5	32
123	Comparison of red and green laser doppler imaging of blood flow. Lasers in Surgery and Medicine, 2004, 35, 191-200.	1.1	32
124	Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. Rheumatology, 2006, 46, 363-364.	0.9	32
125	A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Research and Therapy, 2012, 14, R85.	1.6	32
126	The effect of disease activity on body composition and resting energy expenditure in patients with rheumatoid arthritis. Journal of Inflammation Research, 2011, 4, 61.	1.6	31

#	Article	IF	Citations
127	The influence of measurement location on reliability of quantitative nailfold videocapillaroscopy in patients with SSc. Rheumatology, 2012, 51, 1323-1330.	0.9	31
128	Intra-and inter-observer reliability of nailfold videocapillaroscopy â€" A possible outcome measure for systemic sclerosis-related microangiopathy. Microvascular Research, 2017, 112, 1-6.	1.1	31
129	Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Annals of the Rheumatic Diseases, 2013, 72, 1233-1238.	0.5	30
130	A double-blind, randomized, placebo-controlled crossover trial of the Â2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis. Rheumatology, 2014, 53, 948-952.	0.9	29
131	Identification of IL12RB1 as a Novel Systemic Sclerosis Susceptibility Locus. Arthritis and Rheumatology, 2014, 66, 3521-3523.	2.9	29
132	Ankle brachial pressure index in systemic sclerosis: influence of disease subtype and anticentromere antibody. Rheumatology, 2001, 40, 1102-1105.	0.9	28
133	Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design. Journal of Scleroderma and Related Disorders, 2018, 3, 170-174.	1.0	27
134	Pilot study of dual-wavelength (532 and 633â€ƒnm) laser Doppler imaging and infrared thermography of morphoea. British Journal of Dermatology, 2009, 160, 864-867.	1.4	26
135	Clinical features of childhood localized scleroderma in an incidence cohort. Rheumatology, 2011, 50, 1865-1868.	0.9	26
136	Recent advances in the pathogenesis and management of Raynaud's phenomenon and digital ulcers. Current Opinion in Rheumatology, 2016, 28, 577-585.	2.0	26
137	A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial. Rheumatology, 2014, 53, 1422-1430.	0.9	25
138	Differential diagnosis of critical digital ischemia in systemic sclerosis: Report of five cases and review of the literature. Seminars in Arthritis and Rheumatism, 2016, 46, 209-216.	1.6	25
139	An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis. Journal of Rheumatology, 2017, 44, 1453-1457.	1.0	25
140	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. Journal of Scleroderma and Related Disorders, 2017, 2, 42-49.	1.0	25
141	Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. Arthritis Care and Research, 2020, 72, 723-733.	1.5	25
142	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Journal of Psychosomatic Research, 2020, 139, 110262.	1.2	25
143	Vasodilator iontophoresis a possible new therapy for digital ischaemia in systemic sclerosis?. Rheumatology, 2008, 47, 76-79.	0.9	24
144	Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis. Rheumatology, 2010, 49, 990-996.	0.9	24

#	Article	IF	Citations
145	Systemic sclerosis-related calcinosis. Journal of Scleroderma and Related Disorders, 2016, 1, 194-203.	1.0	24
146	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. Annals of the Rheumatic Diseases, 2021, 80, 1040-1047.	0.5	24
147	Quantitative outcome measures for systemic sclerosis-related Microangiopathy â€“ Reliability of image acquisition in Nailfold Capillaroscopy. Microvascular Research, 2017, 113, 56-59.	1.1	23
148	Points to considerâ€”Raynaudâ€™s phenomenon in systemic sclerosis. Rheumatology, 2017, 56, v45-v48.	0.9	23
149	Automated structure and flow measurement â€” a promising tool in nailfold capillaroscopy. Microvascular Research, 2018, 118, 173-177.	1.1	23
150	Imaging calcinosis in patients with systemic sclerosis by radiography, computerised tomography and magnetic resonance imaging. Seminars in Arthritis and Rheumatism, 2019, 49, 279-282.	1.6	23
151	Leriâ€™s pleonosteosis, a congenital rheumatic disease, results from microduplication at 8q22.1 encompassingGDF6andSDC2and provides insight into systemic sclerosis pathogenesis. Annals of the Rheumatic Diseases, 2015, 74, 1249-1256.	0.5	22
152	Calcinosis preferentially affects the thumb compared to other fingers in patients with systemic sclerosis. Scandinavian Journal of Rheumatology, 2016, 45, 317-320.	0.6	22
153	The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort. Rheumatology, 2019, 58, 468-475.	0.9	22
154	The influence of age on nailfold capillary dimensions in childhood. Journal of Rheumatology, 2000, 27, 797-800.	1.0	22
155	Evidence-based management of Raynaudâ€™s phenomenon. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 317-329.	1.2	21
156	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. Journal of Psychosomatic Research, 2020, 135, 110132.	1.2	21
157	New perspectives in the imaging of Raynaudâ€™s phenomenon. European Journal of Rheumatology, 2020, 7, 212-221.	1.3	21
158	Possible therapeutic use of vasodilator iontophoresis. Microvascular Research, 2005, 69, 89-94.	1.1	20
159	Should all digital ulcers be included in future clinical trials of systemic sclerosis-related digital vasculopathy?. Medical Hypotheses, 2018, 116, 101-104.	0.8	20
160	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. Rheumatology, 2021, 60, 1410-1418.	0.9	20
161	Preliminary Clinical Evaluation of Semi-automated Nailfold Capillaroscopy in the Assessment of Patients with Raynaudâ€™s Phenomenon. Microcirculation, 2011, 18, 440-447.	1.0	19
162	Pilot study of intense pulsed light for the treatment of systemic sclerosis-related telangiectases. British Journal of Dermatology, 2012, 167, 563-569.	1.4	19

#	Article	IF	Citations
163	Further confirmation that digital ulcers are associated with the severity of abnormality on nailfold capillaroscopy in patients with systemic sclerosis. Rheumatology, 2014, 53, 376-377.	0.9	19
164	Thermographic Abnormalities are Associated with Future Digital Ulcers and Death in Patients with Systemic Sclerosis. Journal of Rheumatology, 2016, 43, 1519-1522.	1.0	19
165	Nailfold capillaroscopyâ€"how many fingers should be examined to detect abnormality?. Rheumatology, 2019, 58, 284-288.	0.9	19
166	Three-dimensional optoacoustic imaging of nailfold capillaries in systemic sclerosis and its potential for disease differentiation using deep learning. Scientific Reports, 2020, 10, 16444.	1.6	19
167	Dual wavelength (532 and 633 nm) laser Doppler imaging of plaque psoriasis. British Journal of Dermatology, 2005, 152, 1182-1186.	1.4	18
168	An Automated System for Detecting and Measuring Nailfold Capillaries. Lecture Notes in Computer Science, 2014, 17, 658-665.	1.0	18
169	Non-invasive Imaging of Localised Scleroderma for Assessment of Skin Blood Flow and Structure. Acta Dermato-Venereologica, 2016, 96, 641-644.	0.6	18
170	The assessment of nailfold capillaries: comparison of dermoscopy and nailfold videocapillaroscopy. Rheumatology, 2018, 57, 1115-1116.	0.9	18
171	Raynaudâ€™s phenomenon. Journal of Scleroderma and Related Disorders, 2019, 4, 89-101.	1.0	18
172	Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials. Lancet Rheumatology, The, 2019, 1, e237-e246.	2.2	18
173	Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. Journal of Rheumatology, 1996, 23, 650-3.	1.0	18
174	Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. Nature Reviews Rheumatology, 2022, 18, 276-285.	3.5	18
175	Vascular imaging. Best Practice and Research in Clinical Rheumatology, 2004, 18, 957-979.	1.4	17
176	Noninvasive Measurement of Skin Autofluorescence Is Increased in Patients with Systemic Sclerosis: An Indicator of Increased Advanced Glycation Endproducts?. Journal of Rheumatology, 2012, 39, 1654-1658.	1.0	17
177	Long-term outcome of patients with systemic sclerosis requiring home parenteral nutrition. Clinical Nutrition, 2015, 34, 991-996.	2.3	17
178	LHRH analogue treatment for the prevention of premenstrual attacks of acute porphyria. The Quarterly Journal of Medicine, 1990, 75, 355-63.	1.0	17
179	NEUROLOGICAL INVOLVEMENT IN SYSTEMIC SCLEROSIS. Rheumatology, 1995, 34, 1007-1008.	0.9	16
180	Effects of Iloprost on Microvascular Structure Assessed by Nailfold Videocapillaroscopy: A Pilot Study: Table 1.. Journal of Rheumatology, 2011, 38, 2079-2080.	1.0	16

#	Article	IF	Citations
181	History of surgical debridement, anticentromere antibody, and disease duration are associated with calcinosis in patients with systemic sclerosis. Scandinavian Journal of Rheumatology, 2016, 45, 114-117.	0.6	16
182	Quantitative nailfold capillaroscopyâ€"update and possible next steps. Rheumatology, 2021, 60, 2054-2065.	0.9	16
183	Investigation of anal function in patients with systemic sclerosis.. Annals of the Rheumatic Diseases, 1996, 55, 370-374.	0.5	15
184	A pilot study of acetic acid iontophoresis and ultrasound in the treatment of systemic sclerosis-related calcinosis. British Journal of Rheumatology, 2005, 44, 536-538.	2.5	15
185	Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 2050-2052.	0.5	15
186	Does the Clinical Context Improve the Reliability of Rheumatologists Grading Digital Ulcers in Systemic Sclerosis?. Arthritis Care and Research, 2016, 68, 1340-1345.	1.5	15
187	Elevation of blood lactate and pyruvate levels in acute intermittent porphyria â€" A reflection of haem deficiency?. Clinica Chimica Acta, 1990, 190, 157-162.	0.5	14
188	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology, 2020, 59, 2016-2023.	0.9	14
189	Coexistence of systemic sclerosis and multiple sclerosis. Journal of Neurology, 2004, 251, 1524-1525.	1.8	13
190	Cervical Spine Calcinosis in Systemic Sclerosis. Journal of Rheumatology, 2013, 40, 1617-1618.	1.0	13
191	Vascular diagnostics for Raynaud's phenomenon. Journal of Vascular Diagnostics, 0, , 127.	0.2	13
192	Controversies on the Use of Steroids in Systemic Sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 84-91.	1.0	13
193	Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. Lancet Rheumatology, The, 2021, 3, e175-e184.	2.2	13
194	Giant cell arteritis in a patient with limited cutaneous systemic sclerosis.. Rheumatology, 1999, 38, 479-480.	0.9	12
195	Keloidal scleroderma. Clinical and Experimental Dermatology, 2003, 28, 171-173.	0.6	12
196	Molecular Basis for Dysregulated Activation of <scp>NKX</scp>2â€5 in the Vascular Remodeling of Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 920-931.	2.9	12
197	Tracking digital ulcers in systemic sclerosis: a feasibility study assessing lesion area in patient-recorded smartphone photographs. Annals of the Rheumatic Diseases, 2018, 77, 1382-1384.	0.5	12
198	Comparison between low cost USB nailfold capillaroscopy and videocapillaroscopy: a pilot study. Rheumatology, 2020, 60, 3862-3867.	0.9	12

#	Article	IF	Citations
199	Pressure and pain In Systemic sclerosis/Scleroderma - an evaluation of a simple intervention (PISCES): randomised controlled trial protocol. BMC Musculoskeletal Disorders, 2012, 13, 11.	0.8	11
200	Patient experiences of digital ulcer development and evolution in systemic sclerosis. Rheumatology, 2020, 59, 2156-2158.	0.9	11
201	Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity.. British Journal of Clinical Pharmacology, 1989, 27, 491-497.	1.1	10
202	DNA repair deficiency in systemic lupus erythematosus: cause or consequence of disease and implications for management. Lupus, 1995, 4, 423-424.	0.8	10
203	KCNA5 gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor. Arthritis Research and Therapy, 2012, 14, R273.	1.6	10
204	A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis. Journal of Dermatological Treatment, 2019, 30, 251-257.	1.1	10
205	Quantifying Digital Ulcers in Systemic Sclerosis: Reliability of Computerâ€Assisted Planimetry in Measuring Lesion Size. Arthritis Care and Research, 2018, 70, 486-490.	1.5	10
206	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. Rheumatology, 2022, 61, 4384-4396.	0.9	10
207	Celiprolol and verapamil in the treatment of essential hypertension. American Heart Journal, 1988, 116, 1437-1438.	1.2	9
208	Elevation of hormone-binding globulins in acute intermittent porphyria. Clinica Chimica Acta, 1990, 187, 141-148.	0.5	9
209	Cholelithiasis in patients with variegate porphyria. Journal of Hepatology, 1991, 12, 50-53.	1.8	9
210	PRIMARY RAYNAUD'S PHENOMENON IN EARLY CHILDHOOD. Rheumatology, 1991, 30, 223-225.	0.9	9
211	Mixed connective tissue disease presenting with pneumonitis and pneumatosis intestinalis. Arthritis and Rheumatism, 2000, 43, 704.	6.7	9
212	A local approach to Raynaud phenomenon. Nature Reviews Rheumatology, 2009, 5, 246-247.	3.5	9
213	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). Journal of Rheumatology, 2010, 37, 1673-1679.	1.0	9
214	Analysis of ATP8B4 F436L Missense Variant in a Large Systemic Sclerosis Cohort. Arthritis and Rheumatology, 2017, 69, 1337-1338.	2.9	9
215	A randomised controlled trial of wax baths as an additive therapy to hand exercises in patients with systemic sclerosis. Physiotherapy, 2019, 105, 370-377.	0.2	9
216	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. Journal of Psychosomatic Research, 2021, 140, 110314.	1.2	9

#	Article	IF	Citations
217	Systemic sclerosis skin is a primed microenvironment for soft tissue calcificationâ€”a hypothesis. Rheumatology, 2021, 60, 2517-2527.	0.9	9
218	Raynaud's phenomenon and digital ulcers: advances in evaluation and management. Current Opinion in Rheumatology, 2021, 33, 453-462.	2.0	9
219	State-of-the-art technologies provide new insights linking skin and blood vessel abnormalities in SSc-related disorders. Microvascular Research, 2020, 130, 104006.	1.1	9
220	Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. Lancet Rheumatology, The, 2021, 3, e844-e854.	2.2	9
221	Pilot study assessing pathophysiology and healing of digital ulcers in patients with systemic sclerosis using laser Doppler imaging and thermography. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 100-105.	0.4	9
222	A pilot study using high-frequency ultrasound to measure digital ulcers: a possible outcome measure in systemic sclerosis clinical trials?. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 218-219.	0.4	9
223	Polarisation-sensitive optical coherence tomography measurement of retardance in fibrosis, a non-invasive biomarker in patients with systemic sclerosis. Scientific Reports, 2022, 12, 2893.	1.6	9
224	Lack of interaction between flucloxacillin and methotrexate in pa tien t s with rheumatoid arthritis. British Journal of Clinical Pharmacology, 1996, 41, 223-227.	1.1	8
225	Infected Calcinosis of the Knee in Limited Cutaneous Systemic Sclerosis: Figure 1.. Journal of Rheumatology, 2012, 39, 2043-2044.	1.0	8
226	Polymorphisms in the Interleukin 4, Interleukin 13, and Corresponding Receptor Genes Are Not Associated with Systemic Sclerosis and Do Not Influence Gene Expression. Journal of Rheumatology, 2012, 39, 112-118.	1.0	8
227	Therapeutic implications from the pathogenesis of Raynaudâ€™s phenomenon. Expert Review of Clinical Immunology, 2017, 13, 723-735.	1.3	8
228	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2018, 70, 1646-1652.	1.5	8
229	Frontiers in translational systemic sclerosis research: A focus on the unmet 'cutaneous' clinical needs (Viewpoint). Experimental Dermatology, 2020, 29, 1144-1153.	1.4	8
230	A pilot study of cutaneous oxygenation and perfusion in systemic sclerosisâ€“related digital calcinosis. Rheumatology, 2020, 59, 3109-3111.	0.9	8
231	Lack of interaction between methotrexate and penicillins. British Journal of Rheumatology, 1999, 38, 284-284.	2.5	7
232	Ultrasound findings in finger flexor tendons in systemic sclerosis: A cross-sectional pilot study. Journal of Scleroderma and Related Disorders, 2020, 5, 77-82.	1.0	7
233	HLA-DRB1 associations with rheumatoid arthritis-related pulmonary fibrosis. Scandinavian Journal of Rheumatology, 2014, 43, 75-76.	0.6	6
234	RNASEH2B Related Adult-Onset Interferonopathy. Journal of Clinical Immunology, 2019, 39, 620-622.	2.0	6

#	Article	IF	Citations
235	Percutaneous endoscopic gastrostomy feeding--a life-saving intervention in SSc-myositis overlap with pharyngeal dysfunction. Rheumatology, 2012, 51, 1518-1520.	0.9	5
236	System sclerosis. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, 509-516.	0.2	5
237	Churgâ€“Strauss, a rare cause of intracerebral haemorrhage. Journal of Clinical Neuroscience, 2012, 19, 1177-1178.	0.8	5
238	A longitudinal study of ankle brachial pressure indices in a cohort of patients with systemic sclerosis. Rheumatology, 2014, 53, 2009-2013.	0.9	5
239	Abnormalities of selenium but not of copper homeostasis may drive tissue fibrosis in patients with systemic sclerosis. Rheumatology, 2015, 54, 747-748.	0.9	5
240	Whole finger iontophoresis of sodium nitroprusside to increase blood flow in patients with systemic sclerosis: Influence of concentration. International Journal of Pharmaceutics, 2015, 490, 446-449.	2.6	5
241	Microvascular Response in Patients with Complex Regional Pain Syndrome as Measured by Laser Doppler Imaging. Microcirculation, 2016, 23, 379-383.	1.0	5
242	Quartz Crystal Microbalance Assay of Clinical Calcinosis Samples and Their Synthetic Models Differentiates the Efficacy of Chelation-Based Treatments. ACS Applied Materials & Interfaces, 2017, 9, 27544-27552.	4.0	5
243	Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: a retrospective cohort study. Scandinavian Journal of Rheumatology, 2019, 48, 230-234.	0.6	5
244	cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis. Rheumatology, 2020, 59, 3939-3951.	0.9	5
245	Temperature response to cold challenge and mobile phone thermography as outcome measures for systemic sclerosis-related Raynaudâ€™s phenomenon. Scandinavian Journal of Rheumatology, 2021, 50, 479-484.	0.6	5
246	Raynaud's phenomenon (secondary). Clinical Evidence, 2008, 2008, .	0.2	5
247	Raynaud's phenomenon (secondary). Clinical Evidence, 2014, 2014, .	0.2	5
248	Results from an American pilot survey among Scleroderma Clinical Trials Consortium members on capillaroscopy use and how to best implement nailfold capillaroscopy training. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 151.	0.4	5
249	Advances in palliative care for the patient with scleroderma. Current Opinion in Rheumatology, 1996, 8, 555-560.	2.0	4
250	Mycobacterium chelonae finger infection associated with Raynaud's phenomenon. Annals of the Rheumatic Diseases, 2004, 63, 1178-1179.	0.5	4
251	Raynaudâ€™s Phenomenon and Hand Function in Patients with Rheumatoid Arthritis: Figure 1.. Journal of Rheumatology, 2010, 37, 1358.2-1359.	1.0	4
252	Childrens' and parents' beliefs about childhood onset scleroderma are influenced by child age and physical function impairment. Rheumatology, 2012, 51, 1331-1333.	0.9	4

#	Article	IF	Citations
253	Profound hypomagnesaemia causing symptomatic hypocalcaemia--an underdiagnosed and potentially life-threatening problem in systemic sclerosis?. Rheumatology, 2014, 53, 767-769.	0.9	4
254	Sparing effect of hemiplegia on skin fibrosis and microvascular involvement: Reports of two cases of systemic sclerosis and review of the literature. Seminars in Arthritis and Rheumatism, 2015, 44, 597-601.	1.6	4
255	Management of Raynaudâ€™s Phenomenon and Digital Ulcers. Current Treatment Options in Rheumatology, 2015, 1, 68-81.	0.6	4
256	Imaging digital arteries in systemic sclerosis by tomographic 3-dimensional ultrasound. Rheumatology International, 2021, 41, 1089-1096.	1.5	4
257	Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS). Journal of Scleroderma and Related Disorders, 2021, 6, 146-153.	1.0	4
258	Low body weight and involuntary weight loss are associated with Raynaudâ€™s phenomenon in both men and women. Scandinavian Journal of Rheumatology, 2021, 50, 153-160.	0.6	4
259	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2022, 74, 1300-1310.	1.5	4
260	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. Trials, 2021, 22, 856.	0.7	4
261	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. Clinical and Experimental Rheumatology, 2015, 33, S31-5.	0.4	4
262	Manchester experience in establishing a part-time MSc course in rheumatology. Rheumatology, 1998, 37, 1020-1022.	0.9	3
263	Development of agents for the treatment of systemic sclerosis. Expert Opinion on Investigational Drugs, 2001, 10, 1255-1264.	1.9	3
264	Raynaudâ€™s phenomenon. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 146-155.	0.4	3
265	Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology, 2010, 49, 1607-1608.	0.9	3
266	Raynaudâ€™s Phenomenon. , 2012, , 313-329.		3
267	Simulating nailfold capillaroscopy sequences to evaluate algorithms for blood flow estimation. , 2013, 2013, 2636-9.		3
268	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. Body Image, 2017, 20, 99-106.	1.9	3
269	A synonymous variant in TREX1 is associated with systemic sclerosis and severe digital ischaemia. Scandinavian Journal of Rheumatology, 2017, 46, 77-78.	0.6	3
270	Systemic sclerosis: clinical features and management. Medicine, 2018, 46, 131-139.	0.2	3

#	Article	IF	Citations
271	SAT0296â€…FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A SCLERODERMA PATTERN FROM A NON-SCLERODERMA PATTERN. , 2019, , .		3
272	Systemic sclerosis-related digital ulcers; a pilot study of cutaneous oxygenation and perfusion. Rheumatology, 2020, 59, 3573-3575.	0.9	3
273	Impact and associates of digital pitting in patients with systemic sclerosis: a pilot study. Scandinavian Journal of Rheumatology, 2020, 49, 239-243.	0.6	3
274	Improved Diagnosis of Systemic Sclerosis Using Nailfold Capillary Flow. Lecture Notes in Computer Science, 2016, , 344-352.	1.0	3
275	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. Pilot and Feasibility Studies, 2022, 8, 45.	0.5	3
276	Biochemical investigation of hepatoerythropoietic porphyria â€" homozygous porphyria cutanea tarda. Biochemical Society Transactions, 1988, 16, 829-830.	1.6	2
277	Comment on: Sparing of the thumb in Raynaud's phenomenon: reply. Rheumatology, 2008, 47, 1260-1260.	0.9	2
278	An investigation into the blood-flow characteristics of telangiectatic skin lesions in systemic sclerosis using dual-wavelength laser Doppler imaging. Clinical and Experimental Dermatology, 2009, 34, 618-620.	0.6	2
279	Testing for Hypoxia in Forearm Skin of Patients with Systemic Sclerosis, Assessed by Pimonidazole. Journal of Rheumatology, 2010, 37, 1968.2-1969.	1.0	2
280	Comment on: A multicentre study on the reliability of qualitative and quantitative nailfold videocapillaroscopy assessment: reply. Rheumatology, 2012, 51, 1922-1922.	0.9	2
281	Evidence for a clinical association between body mass index and malabsorption in patients with systemic sclerosis. Scandinavian Journal of Rheumatology, 2015, 44, 341-342.	0.6	2
282	Clinical Images: Systemic sclerosis-related telangiectases. Arthritis and Rheumatism, 2011, 63, 572-572.	6.7	1
283	Dr. Murray, et al reply. Journal of Rheumatology, 2013, 40, 206.2-206.	1.0	1
284	Pilot study to visualise and measure skin tissue oxygenation, erythema, total haemoglobin and melanin content using index maps in healthy controls. , 2014, , .		1
285	286.â€ƒPilot Study of Multispectral Imaging to Measure Skin Oxygenation in Healthy Controls and Patients with Systemic Sclerosis and Primary Raynaudâ€™s Phenomenon. Rheumatology, 2015, , .	0.9	1
286	Longitudinal nailfold capillaroscopy tracking of microangiopathic changes in systemic sclerosis. Rheumatology, 2018, 57, 1554-1554.	0.9	1
287	127â€ƒQuality of life in patients with connective tissue diseases: results from the Lupus Extended Autoimmune Phenotype (LEAP) study. Rheumatology, 2018, 57, .	0.9	1
288	Do thermographic parameters help to classify patients with early systemic sclerosis?. Rheumatology, 2019, 58, 1105-1106.	0.9	1

#	Article	IF	Citations
289	Raynaudâ€™s Phenomenon, Digital Ulcers and Nailfold Capillaroscopy. , 2017, , 297-316.		1
290	Idiopathic haemochromatosis in a young female with amenorrhoea. Journal of the Royal Society of Medicine, 1989, 82, 556-8.	1.1	1
291	Clinical Images: Pachydermoperiostosis. Arthritis and Rheumatism, 2010, 62, 1538-1538.	6.7	0
292	Treatment options in Raynaud's phenomenon. Expert Opinion on Orphan Drugs, 2014, 2, 271-282.	0.5	0
293	Raynaudâ€™s Phenomenon. , 2018, , 445-451.		0
294	157â€ƒAutomated analysis of nailfold images from handheld devices. Rheumatology, 2018, 57, .	0.9	0
295	159â€ƒDermoscopy versus videocapillaroscopy in the assessment of nailfold capillaroscopy images in patients with systemic sclerosis and healthy controls. Rheumatology, 2018, 57, .	0.9	0
296	Connective tissue diseases (excluding SLE). Best Practice and Research in Clinical Rheumatology, 2020, 34, 101487.	1.4	0
297	Raynaudâ€™s Phenomenon. , 2006, , 313-319.		0
298	Raynaudâ€™s Phenomenon. , 2010, , 387-393.		0
299	A 22-Year-Old Woman with Raynaudâ€™s Phenomenon but No Other Symptoms and No Abnormalities on Examination. , 2011, , 23-29.		0
300	Corrigendum to: Systemic sclerosis-related digital ulcers; a pilot study of cutaneous oxygenation and perfusion. Rheumatology, 2021, 60, 2490-2490.	0.9	0
301	Primary Raynaudâ€™s Phenomenon. , 2015, , 81-93.		0
302	Critical Ischemia in Patients with Raynaudâ€™s Phenomenon. , 2017, , 257-266.		0
303	Raynaudâ€™s Phenomenon and Ulcers. , 2019, , 45-62.		0
304	Associations with digital pitting in patients with systemic sclerosis: results of a retrospective analysis. Scandinavian Journal of Rheumatology, 2021, , 1-2.	0.6	0
305	Systemic sclerosis: clinical features and management. Medicine, 2021, , .	0.2	0
306	No significant effects of sodium aurothiomalate on haem metabolism and mixed function oxygenase activity in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 1999, 17, 461-2.	0.4	0

#	Article	IF	Citations
307	P230â€ƒFeasibility study of mobile phone photography as a possible outcome measure of systemic sclerosis-related digital ulcers. Rheumatology, 2022, 61, .	0.9	0
308	P228â€ƒMobile phone thermal imaging as an ambulatory assessment tool in Raynaudâ€™s phenomenon. Rheumatology, 2022, 61, .	0.9	0
309	The need to accurately measure energy intake and expenditure in patients with systemic sclerosis. Journal of Scleroderma and Related Disorders, 0, , 239719832210957.	1.0	0